II 

Calendar No. 441 

114TH CONGRESS 

2D SESSION S. 1455 

To provide access to medication-assisted therapy, and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

MAY 22, 2015 

Mr. MARKEY (for himself, Mr. PAUL, Mrs. FEINSTEIN, Mr. DURBIN, Ms. 

HIRONO, Mr. BROWN, Ms. BALDWIN, Mr. FRANKEN, Mr. CASEY, Mrs. 

SHAHEEN, Mr. KING, Mr. LEAHY, Mr. SANDERS, Ms. COLLINS, Mr. 

MERKLEY, Mr. REED, Mr. MURPHY, Mr. MENENDEZ, Mr. HATCH, and 

Mrs. GILLIBRAND) introduced the following bill; which was read twice 

and referred to the Committee on Health, Education, Labor, and Pensions 

APRIL 27, 2016 

Reported by Mr. ALEXANDER, with an amendment 

[Strike out all after the enacting clause and insert the part printed in italic] 

A BILL 

To provide access to medication-assisted therapy, and for 

other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Recovery Enhancement 

5 for Addiction Treatment Act’’ or the ‘‘TREAT Act’’. 


sradovich on DSK3TPTVN1PROD with BILLS
2 

•S 1455 RS

1 SEC. 2. FINDINGS. 

2 Congress finds the following: 

3 (1) Overdoses from opioids have increased dra4 matically in the United States. 

5 (2) Deaths from drug overdose, largely from 

6 prescription pain relievers, have tripled among men 

7 and increased five-fold among women over the past 

8 decade. 

9 (3) Nationwide, drug overdoses now claim more 

10 lives than car accidents. 

11 (4) Opioid addiction is a chronic disease that, 

12 untreated, places a large burden on the healthcare 

13 system. Roughly 475,000 emergency room visits 

14 each year are attributable to the misuse and abuse 

15 of opioid pain medication. 

16 (5) Effective medication-assisted treatment for 

17 opioid addiction, in combination with counseling and 

18 behavioral therapies, can decrease overdose deaths, 

19 be cost-effective, reduce transmissions of HIV and 

20 viral hepatitis, and reduce other social harms such 

21 as criminal activity. 

22 (6) Effective medication-assisted treatment pro23 grams for opioid addiction should include multiple 

24 components, including medications, cognitive and be25 havioral supports and interventions, and drug test26 ing. 


sradovich on DSK3TPTVN1PROD with BILLS
3 

•S 1455 RS

1 (7) Effective medication-assisted treatment pro2 grams for opioid addiction may use a team of staff 

3 members, in addition to a prescribing provider, to 

4 deliver comprehensive care. 

5 (8) Access to medication-assisted treatments, 

6 including office-based buprenorphine opioid treat7 ment, remains limited in part due to current prac8 tice regulations and an insufficient number of pro9 viders. 

10 (9) More than 10 years of experience in the 

11 United States with office-based buprenorphine opioid 

12 treatment has informed best practices for delivering 

13 successful, high quality care. 

14 SEC. 3. EXPANSION OF PATIENT LIMITS UNDER WAIVER. 

15 Section 303(g)(2)(B) of the Controlled Substances 

16 Act (21 U.S.C. 823(g)(2)(B)) is amended— 

17 (1) in clause (i), by striking ‘‘physician’’ and in18 serting ‘‘practitioner’’; 

19 (2) in clause (iii)— 

20 (A) by striking ‘‘30’’ and inserting ‘‘100’’; 

21 and 

22 (B) by striking ‘‘, unless, not sooner’’ and 

23 all that follows through the end and inserting a 

24 period; and 


sradovich on DSK3TPTVN1PROD with BILLS
4 

•S 1455 RS

1 (3) by inserting at the end the following new 

2 clause: 

3 ‘‘(iv) Not earlier than 1 year after the date 

4 on which a qualifying practitioner obtained an 

5 initial waiver pursuant to clause (iii), the quali6 fying practitioner may submit a second notifica7 tion to the Secretary of the need and intent of 

8 the qualifying practitioner to treat an unlimited 

9 number of patients, if the qualifying practi10 tioner— 

11 ‘‘(I)(aa) satisfies the requirements of 

12 item (aa), (bb), (cc), or (dd) of subpara13 graph (G)(ii)(I); and 

14 ‘‘(bb) agrees to fully participate in the 

15 Prescription Drug Monitoring Program of 

16 the State in which the qualifying practi17 tioner is licensed, pursuant to applicable 

18 State guidelines; or 

19 ‘‘(II)(aa) satisfies the requirements of 

20 item (ee), (ff), or (gg) of subparagraph 

21 (G)(ii)(I); 

22 ‘‘(bb) agrees to fully participate in the 

23 Prescription Drug Monitoring Program of 

24 the State in which the qualifying practiVerDate Sep 11 2014 21:22 Apr 27, 2016 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6401 E:\BILLS\S1455.RS S1455

sradovich on DSK3TPTVN1PROD with BILLS
5 

•S 1455 RS

1 tioner is licensed, pursuant to applicable 

2 State guidelines; 

3 ‘‘(cc) practices in a qualified practice 

4 setting; and 

5 ‘‘(dd) has completed not less than 24 

6 hours of training (through classroom situa7 tions, seminars at professional society 

8 meetings, electronic communications, or 

9 otherwise) with respect to the treatment 

10 and management of opiate-dependent pa11 tients for substance use disorders provided 

12 by the American Society of Addiction Med13 icine, the American Academy of Addiction 

14 Psychiatry, the American Medical Associa15 tion, the American Osteopathic Associa16 tion, the American Psychiatric Association, 

17 or any other organization that the Sec18 retary determines is appropriate for pur19 poses of this subclause.’’. 

20 SEC. 4. DEFINITIONS. 

21 Section 303(g)(2)(G) of the Controlled Substances 

22 Act (21 U.S.C. 823(g)(2)(G)) is amended— 

23 (1) by striking clause (ii) and inserting the fol24 lowing: 


sradovich on DSK3TPTVN1PROD with BILLS
6 

•S 1455 RS

1 ‘‘(ii) The term ‘qualifying practitioner’ 

2 means the following: 

3 ‘‘(I) A physician who is licensed under 

4 State law and who meets 1 or more of the 

5 following conditions: 

6 ‘‘(aa) The physician holds a 

7 board certification in addiction psychi8 atry from the American Board of 

9 Medical Specialties. 

10 ‘‘(bb) The physician holds an ad11 diction certification from the Amer12 ican Society of Addiction Medicine. 

13 ‘‘(cc) The physician holds a 

14 board certification in addiction medi15 cine from the American Osteopathic 

16 Association. 

17 ‘‘(dd) The physician holds a 

18 board certification from the American 

19 Board of Addiction Medicine. 

20 ‘‘(ee) The physician has com21 pleted not less than 8 hours of train22 ing (through classroom situations, 

23 seminars at professional society meet24 ings, electronic communications, or 

25 otherwise) with respect to the treatVerDate Sep 11 2014 21:22 Apr 27, 2016 Jkt 059200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6401 E:\BILLS\S1455.RS S1455

sradovich on DSK3TPTVN1PROD with BILLS
7 

•S 1455 RS

1 ment and management of opiate-de2 pendent patients for substance use 

3 disorders provided by the American 

4 Society of Addiction Medicine, the 

5 American Academy of Addiction Psy6 chiatry, the American Medical Asso7 ciation, the American Osteopathic As8 sociation, the American Psychiatric 

9 Association, or any other organization 

10 that the Secretary determines is ap11 propriate for purposes of this sub12 clause. 

13 ‘‘(ff) The physician has partici14 pated as an investigator in 1 or more 

15 clinical trials leading to the approval 

16 of a narcotic drug in schedule III, IV, 

17 or V for maintenance or detoxification 

18 treatment, as demonstrated by a 

19 statement submitted to the Secretary 

20 by this sponsor of such approved 

21 drug. 

22 ‘‘(gg) The physician has such 

23 other training or experience as the 

24 Secretary determines will demonstrate 

25 the ability of the physician to treat 


sradovich on DSK3TPTVN1PROD with BILLS
8 

•S 1455 RS

1 and manage opiate-dependent pa2 tients. 

3 ‘‘(II) A nurse practitioner or physi4 cian assistant who is licensed under State 

5 law and meets all of the following condi6 tions: 

7 ‘‘(aa) The nurse practitioner or 

8 physician assistant is licensed under 

9 State law to prescribe schedule III, 

10 IV, or V medications for pain. 

11 ‘‘(bb) The nurse practitioner or 

12 physician assistant satisfies 1 or more 

13 of the following: 

14 ‘‘(AA) Has completed not 

15 fewer than 24 hours of training 

16 (through classroom situations, 

17 seminars at professional society 

18 meetings, electronic communica19 tions, or otherwise) with respect 

20 to the treatment and manage21 ment of opiate-dependent pa22 tients for substance use disorders 

23 provided by the American Society 

24 of Addiction Medicine, the Amer25 ican Academy of Addiction PsyVerDate Sep 11 2014 21:22 Apr 27, 2016 Jkt 059200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6401 E:\BILLS\S1455.RS S1455

sradovich on DSK3TPTVN1PROD with BILLS
9 

•S 1455 RS

1 chiatry, the American Medical 

2 Association, the American Osteo3 pathic Association, the American 

4 Psychiatric Association, or any 

5 other organization that the Sec6 retary determines is appropriate 

7 for purposes of this subclause. 

8 ‘‘(BB) Has such other train9 ing or experience as the Sec10 retary determines will dem11 onstrate the ability of the nurse 

12 practitioner or physician assist13 ant to treat and manage opiate14 dependent patients. 

15 ‘‘(cc) The nurse practitioner or 

16 physician assistant practices under 

17 the supervision of a licensed physician 

18 who holds an active waiver to pre19 scribe schedule III, IV, or V narcotic 

20 medications for opioid addiction ther21 apy, and— 

22 ‘‘(AA) the supervising physi23 cian satisfies the conditions of 

24 item (aa), (bb), (cc), or (dd) of 

25 subclause (I); or 


sradovich on DSK3TPTVN1PROD with BILLS
10 

•S 1455 RS

1 ‘‘(BB) both the supervising 

2 physician and the nurse practi3 tioner or physician assistant 

4 practice in a qualified practice 

5 setting. 

6 ‘‘(III) A nurse practitioner who is li7 censed under State law and meets all of 

8 the following conditions: 

9 ‘‘(aa) The nurse practitioner is li10 censed under State law to prescribe 

11 schedule III, IV, or V medications for 

12 pain. 

13 ‘‘(bb) The nurse practitioner has 

14 training or experience that the Sec15 retary determines demonstrates spe16 cialization in the ability to treat opi17 ate-dependent patients, such as a cer18 tification in addiction specialty accred19 ited by the American Board of Nurs20 ing Specialties or the National Com21 mission for Certifying Agencies, or a 

22 certification in addiction nursing as a 

23 Certified Addiction Registered 

24 Nurse—Advanced Practice. 


sradovich on DSK3TPTVN1PROD with BILLS
11 

•S 1455 RS

1 ‘‘(cc) In accordance with State 

2 law, the nurse practitioner prescribes 

3 opioid addiction therapy in collabora4 tion with a physician who holds an ac5 tive waiver to prescribe schedule III, 

6 IV, or V narcotic medications for 

7 opioid addiction therapy. 

8 ‘‘(dd) The nurse practitioner 

9 practices in a qualified practice set10 ting.’’; and 

11 (2) by adding at the end the following: 

12 ‘‘(iii) The term ‘qualified practice setting’ 

13 means 1 or more of the following treatment set14 tings: 

15 ‘‘(I) A National Committee for Qual16 ity Assurance-recognized Patient-Centered 

17 Medical Home or Patient-Centered Spe18 cialty Practice. 

19 ‘‘(II) A Centers for Medicaid & Medi20 care Services-recognized Accountable Care 

21 Organization. 

22 ‘‘(III) A clinical facility administered 

23 by the Department of Veterans Affairs, 

24 Department of Defense, or Indian Health 

25 Service. 


sradovich on DSK3TPTVN1PROD with BILLS
12 

•S 1455 RS

1 ‘‘(IV) A Behavioral Health Home ac2 credited by the Joint Commission. 

3 ‘‘(V) A Federally-qualified health cen4 ter (as defined in section 1905(l)(2)(B) of 

5 the Social Security Act (42 U.S.C. 

6 1396d(l)(2)(B))) or a Federally-qualified 

7 health center look-alike. 

8 ‘‘(VI) A Substance Abuse and Mental 

9 Health Services-certified Opioid Treatment 

10 Program. 

11 ‘‘(VII) A clinical program of a State 

12 or Federal jail, prison, or other facility 

13 where individuals are incarcerated. 

14 ‘‘(VIII) A clinic that demonstrates 

15 compliance with the Model Policy on 

16 DATA 2000 and Treatment of Opioid Ad17 diction in the Medical Office issued by the 

18 Federation of State Medical Boards. 

19 ‘‘(IX) A treatment setting that is part 

20 of an Accreditation Council for Graduate 

21 Medical Education, American Association 

22 of Colleges of Osteopathic Medicine, or 

23 American Osteopathic Association-accred24 ited residency or fellowship training pro25 gram. 


sradovich on DSK3TPTVN1PROD with BILLS
13 

•S 1455 RS

1 ‘‘(X) Any other practice setting ap2 proved by a State regulatory board or 

3 State Medicaid Plan to provide addiction 

4 treatment services. 

5 ‘‘(XI) Any other practice setting ap6 proved by the Secretary.’’. 

7 SEC. 5. GAO EVALUATION. 

8 Two years after the date on which the first notifica9 tion under clause (iv) of section 303(g)(2)(B) of the Con10 trolled Substances Act (21 U.S.C. 823(g)(2)(B)), as added 

11 by this Act, is received by the Secretary of Health and 

12 Human Services, the Comptroller General of the United 

13 States shall initiate an evaluation of the effectiveness of 

14 the amendments made by this Act, which shall include an 

15 evaluation of— 

16 (1) any changes in the availability and use of 

17 medication-assisted treatment for opioid addiction; 

18 (2) the quality of medication-assisted treatment 

19 programs; 

20 (3) the integration of medication-assisted treat21 ment with routine healthcare services; 

22 (4) diversion of opioid addiction treatment 

23 medication; 

24 (5) changes in State or local policies and legis25 lation relating to opioid addiction treatment; 


sradovich on DSK3TPTVN1PROD with BILLS
14 

•S 1455 RS

1 (6) the use of nurse practitioners and physician 

2 assistants who prescribe opioid addiction medication; 

3 (7) the use of Prescription Drug Monitoring 

4 Programs by waived practitioners to maximize safety 

5 of patient care and prevent diversion of opioid addic6 tion medication; 

7 (8) the findings of Drug Enforcement Adminis8 tration inspections of waived practitioners, including 

9 the frequency with which the Drug Enforcement Ad10 ministration finds no documentation of access to be11 havioral health services; and 

12 (9) the effectiveness of cross-agency collabora13 tion between Department of Health and Human 

14 Services and the Drug Enforcement Administration 

15 for expanding effective opioid addiction treatment. 

16 SECTION 1. SHORT TITLE. 

17 This Act may be cited as the ‘‘Recovery Enhancement 

18 for Addiction Treatment Act’’ or the ‘‘TREAT Act’’. 

19 SEC. 2. EXPANSION OF PATIENT LIMITS UNDER WAIVER. 

20 Section 303(g)(2)(B) of the Controlled Substances Act 

21 (21 U.S.C. 823(g)(2)(B)) is amended— 

22 (1) in clause (i), by striking ‘‘physician’’ and in23 serting ‘‘practitioner’’; 

24 (2) in clause (iii)— 


sradovich on DSK3TPTVN1PROD with BILLS
15 

•S 1455 RS

1 (A) by striking ‘‘The total number’’ and in2 serting ‘‘(I) The total number’’; 

3 (B) by striking ‘‘30’’ and inserting ‘‘100’’; 

4 (C) by striking ‘‘, unless, not sooner’’ and 

5 all that follows through ‘‘of this subparagraph’’; 

6 and 

7 (D) by adding at the end the following: 

8 ‘‘(II) If a patient is referred by a qualifying 

9 practitioner that is a physician to another quali10 fying practitioner that is a physician that pro11 vides short-term services (such as induction or ti12 tration), the patient shall only be included in the 

13 total number of such patients of the qualifying 

14 physician that makes the referral. 

15 ‘‘(III) In this clause, the term ‘the total 

16 number of such patients’ shall not include a pa17 tient to whom a qualifying practitioner that is 

18 a physician meeting the requirements described 

19 in clause (iv)(I), or an authorized agent of such 

20 qualifying practitioner that is a physician, di21 rectly administers such drugs or combination 

22 drugs.’’; and 

23 (4) by adding at the end the following: 

24 ‘‘(iv) Not earlier than 1 year after the date on 

25 which a qualifying practitioner that is a physician 


sradovich on DSK3TPTVN1PROD with BILLS
16 

•S 1455 RS

1 obtained an initial waiver pursuant to clause (iii), 

2 such qualifying practitioner may submit a second no3 tification to the Secretary of the need and intent of 

4 such qualifying practitioner to treat up to 500 pa5 tients, if such qualifying practitioner— 

6 ‘‘(I)(aa) satisfies the requirements of item (aa), 

7 (bb), (cc), or (dd) of subparagraph (G)(ii)(I); and 

8 ‘‘(bb) agrees to fully participate in the Prescrip9 tion Drug Monitoring Program of the State in which 

10 the qualifying practitioner is licensed, pursuant to 

11 applicable State guidelines; or 

12 ‘‘(II)(aa) satisfies the requirements of item (ee), 

13 (ff), or (gg) of subparagraph (G)(ii)(I); 

14 ‘‘(bb) agrees to fully participate in the Prescrip15 tion Drug Monitoring Program of the State in which 

16 the qualifying practitioner is licensed, pursuant to 

17 applicable State guidelines; and 

18 ‘‘(cc) has completed not less than 24 hours of 

19 training (through classroom situations, seminars at 

20 professional society meetings, electronic communica21 tions, or otherwise) with respect to the treatment and 

22 management of opiate-dependent patients for sub23 stance use disorders provided by the American Society 

24 of Addiction Medicine, the American Academy of Ad25 diction Psychiatry, the American Medical AssociaVerDate Sep 11 2014 21:22 Apr 27, 2016 Jkt 059200 PO 00000 Frm 00016 Fmt 6652 Sfmt 6203 E:\BILLS\S1455.RS S1455

sradovich on DSK3TPTVN1PROD with BILLS
17 

•S 1455 RS

1 tion, the American Osteopathic Association, the Amer2 ican Psychiatric Association, or any other organiza3 tion that the Secretary determines is appropriate for 

4 purposes of this subclause. 

5 ‘‘(v) The qualifying practitioner shall maintain 

6 records relating to the dispensing of drugs or com7 binations of drugs to treat patients under this para8 graph, including— 

9 ‘‘(I) whether the qualifying practitioner 

10 provides counseling services on-site, and how fre11 quently patients are using such services; 

12 ‘‘(II) whether the qualifying practitioner re13 ferred patients for counseling services off-site, the 

14 percentage of the patients of the qualifying prac15 titioner using such services, and how frequently 

16 the patients are using such services; and 

17 ‘‘(III) the frequency with which patients 

18 being treated under this paragraph terminate the 

19 treatment against medical advice.’’. 

20 SEC. 3. DEFINITIONS. 

21 Section 303(g)(2)(G) of the Controlled Substances Act 

22 (21 U.S.C. 823(g)(2)(G)) is amended by striking clause (ii) 

23 and inserting the following: 

24 ‘‘(ii) The term ‘qualifying practitioner’ 

25 means the following: 


sradovich on DSK3TPTVN1PROD with BILLS
18 

•S 1455 RS

1 ‘‘(I) A physician who is licensed under 

2 State law and who meets 1 or more of the 

3 following conditions: 

4 ‘‘(aa) The physician holds a board 

5 certification in addiction psychiatry or 

6 addiction medicine from the American 

7 Board of Medical Specialties. 

8 ‘‘(bb) The physician holds an ad9 diction certification from the American 

10 Society of Addiction Medicine or the 

11 American Board of Addiction Medi12 cine. 

13 ‘‘(cc) The physician holds a board 

14 certification in addiction medicine 

15 from the American Osteopathic Asso16 ciation. 

17 ‘‘(dd) The physician holds a board 

18 certification from the American Board 

19 of Addiction Medicine. 

20 ‘‘(ee) The physician has completed 

21 not less than 8 hours of training 

22 (through classroom situations, semi23 nars at professional society meetings, 

24 electronic communications, or other25 wise) with respect to the treatment and 


sradovich on DSK3TPTVN1PROD with BILLS
19 

•S 1455 RS

1 management of opiate-dependent pa2 tients for substance use disorders pro3 vided by the American Society of Ad4 diction Medicine, the American Acad5 emy of Addiction Psychiatry, the 

6 American Medical Association, the 

7 American Osteopathic Association, the 

8 American Psychiatric Association, or 

9 any other organization that the Sec10 retary determines is appropriate for 

11 purposes of this subclause, after notice 

12 and the opportunity for comment. 

13 ‘‘(ff) The physician has partici14 pated as an investigator in 1 or more 

15 clinical trials leading to the approval 

16 of a narcotic drug in schedule III, IV, 

17 or V for maintenance or detoxification 

18 treatment, as demonstrated by a state19 ment submitted to the Secretary by 

20 this sponsor of such approved drug. 

21 ‘‘(gg) The physician has such 

22 other training or experience as the Sec23 retary determines will demonstrate the 

24 ability of the physician to treat and 

25 manage opiate dependent patients. 


sradovich on DSK3TPTVN1PROD with BILLS
20 

•S 1455 RS

1 ‘‘(II) A nurse practitioner or physician 

2 assistant who is licensed under State law 

3 and meets all of the following conditions: 

4 ‘‘(aa) The nurse practitioner or 

5 physician assistant is licensed under 

6 State law to prescribe schedule III, IV, 

7 or V medications. 

8 ‘‘(bb) The nurse practitioner or 

9 physician assistant has completed not 

10 fewer than 24 hours of training 

11 (through classroom situations, semi12 nars at professional society meetings, 

13 electronic communications, or other14 wise) with respect to the treatment and 

15 management of opiate-dependent pa16 tients for substance use disorders pro17 vided by the American Society of Ad18 diction Medicine, the American Acad19 emy of Addiction Psychiatry, the 

20 American Medical Association, the 

21 American Osteopathic Association, the 

22 American Psychiatric Association, the 

23 American Association of Nurse Practi24 tioners, the American Academy of Phy25 sician Assistants, or any other organiVerDate Sep 11 2014 21:22 Apr 27, 2016 Jkt 059200 PO 00000 Frm 00020 Fmt 6652 Sfmt 6203 E:\BILLS\S1455.RS S1455

sradovich on DSK3TPTVN1PROD with BILLS
21 

•S 1455 RS

1 zation that the Secretary determines is 

2 appropriate for purposes of this sub3 clause, after notice and opportunity for 

4 comment. 

5 ‘‘(cc) If required by State law, the 

6 nurse practitioner or physician assist7 ant prescribes opioid addiction therapy 

8 in collaboration with or under the su9 pervision of, as applicable, a physi10 cian.’’. 

11 SEC. 4. STATE FLEXIBILITY. 

12 Section 303(g)(2) of the Controlled Substances Act (21 

13 U.S.C. 823(g)(2)) is amended by striking subparagraphs (I) 

14 and (J), and inserting the following: 

15 ‘‘(I) Notwithstanding section 708, nothing in 

16 this paragraph shall be construed to preempt any 

17 State law that— 

18 ‘‘(i) permits a qualifying practitioner to 

19 dispense narcotic drugs in schedule III, IV, or V, 

20 or combinations of such drugs, for maintenance 

21 or detoxification treatment in accordance with 

22 this paragraph to a total number of patients 

23 that is more than 30 or less than the total num24 ber applicable to the qualifying practitioner 

25 under clause (iv) of subparagraph (B) if a State 


sradovich on DSK3TPTVN1PROD with BILLS
22 

•S 1455 RS

1 enacts a law modifying such total number and 

2 the Attorney General is notified by the State of 

3 such modification; or 

4 ‘‘(ii) requires a qualifying practitioner to 

5 comply with additional requirements relating to 

6 the dispensing of narcotic drugs in schedule III, 

7 IV, or V, or combinations of such drugs, includ8 ing requirements relating to the practice setting 

9 in which the qualifying practitioner practices 

10 and education, training, and reporting require11 ments.’’. 

12 SEC. 5. UPDATE REGULATIONS. 

13 Not later than 1 year after the date of enactment of 

14 this Act, the Attorney General shall update regulations re15 garding waived practitioners (as amended by this Act) to 

16 include nurse practitioners and physician assistants to en17 sure the quality of patient care and prevent diversion. 

18 SEC. 6. EVALUATIONS. 

19 (a) DEFINITION.—In this section, the term ‘‘appro20 priate committees of Congress’’ means— 

21 (1) the Committee on Health, Education, Labor, 

22 and Pensions and the Committee on the Judiciary of 

23 the Senate; and 


sradovich on DSK3TPTVN1PROD with BILLS
23 

•S 1455 RS

1 (2) the Committee on Energy and Commerce and 

2 the Committee on the Judiciary of the House of Rep3 resentatives. 

4 (b) HHS.—Not later than 2 years after the date of 

5 enactment of this Act, the Secretary of Health and Human 

6 Services, in coordination with the Attorney General, shall 

7 submit to the appropriate committees of Congress a report 

8 on the effect on the amendments made by this title on the 

9 availability of evidence-based treatment and any increased 

10 risk in diversion, including the impact of nurse practi11 tioners and physician assistants as qualifying practi12 tioners. 

13 (c) GAO.— 

14 (1) IN GENERAL.—Four years after the date on 

15 which the first notification under clause (iv) of sec16 tion 303(g)(2)(B) of the Controlled Substances Act (21 

17 U.S.C. 823(g)(2)(B)), as added by this Act, is received 

18 by the Secretary of Health and Human Services, the 

19 Comptroller General of the United States shall ini20 tiate an evaluation of the effectiveness of the amend21 ments made by this Act, which shall include an eval22 uation of— 

23 (A) any changes in the availability and use 

24 of medication-assisted treatment for opioid ad25 diction; 


sradovich on DSK3TPTVN1PROD with BILLS
24 

•S 1455 RS

1 (B) the quality of medication-assisted treat2 ment programs; 

3 (C) the integration of medication-assisted 

4 treatment with routine healthcare services; 

5 (D) diversion of opioid addiction treatment 

6 medication; 

7 (E) changes in State or local policies and 

8 legislation relating to opioid addiction treat9 ment; 

10 (F) the use of nurse practitioners and phy11 sician assistants who prescribe opioid addiction 

12 medication; 

13 (G) the use of Prescription Drug Moni14 toring Programs by waived practitioners to 

15 maximize safety of patient care and prevent di16 version of opioid addiction medication; 

17 (H) the findings of Drug Enforcement 

18 Agency inspections of waived practitioners, in19 cluding the frequency with which the Drug En20 forcement Agency finds no documentation of ac21 cess to behavioral health services; and 

22 (I) the effectiveness of cross-agency collabo23 ration between Department of Health and 

24 Human Services and the Drug Enforcement 


sradovich on DSK3TPTVN1PROD with BILLS
25 

•S 1455 RS

1 Agency for expanding effective opioid addiction 

2 treatment. 

3 (2) REPORT.—The Comptroller General shall 

4 submit to the appropriate committees of Congress a 

5 report regarding the evaluation conducted under 

6 paragraph (1). 


sradovich on DSK3TPTVN1PROD with BILLS
Calendar No. 441 

114TH CONGRESS 

2D SESSION S. 1455 

A BILL 

To provide access to medication-assisted therapy, 

and for other purposes. 

APRIL 27, 2016 

Reported with an amendment 


sradovich on DSK3TPTVN1PROD with BILLS